Organon & Company (OGN) Financial Statements

Organon's financial quality is a tale of two halves. On the positive side, its free cash flow generation is outstanding, with a 34.0% FCF yield far exceeding the framework's >10-15% target, indicating strong cash conversion. Its 24.9% Return on Equity (ROE) also surpasses the high-quality threshold of 15-20%. However, these strengths are severely challenged by other factors. Revenue growth is negative at -5.3% YoY, failing the framework's test for consistent, double-digit growth. The balance sheet is a primary concern, with a Debt/Equity ratio of 11.5, indicating extreme leverage that is far outside the favourable range of less than 1.0x Debt/EBITDA. This heavy debt load creates significant financial risk. While the 13.3% operating margin shows the underlying business is profitable, the 3.0% net profit margin suggests interest expenses are a major burden. For a value investor, the analysis reveals a company with a cash-generative core operation but one that is financially strained, with quality heavily dependent on its ability to manage debt while navigating revenue declines. The growth assessment is clearly unfavourable based on the current trajectory. Analysis based on data as of 2024-05-15.